These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8878817)

  • 41. Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical development.
    Dean NM; McKay RA; Holmlund J
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):147-51. PubMed ID: 9593055
    [No Abstract]   [Full Text] [Related]  

  • 42. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
    Branch AD
    Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.
    Dean NM; McKay R
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11762-6. PubMed ID: 7972137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antisense oligonucleotides targeting translation inhibitory elements in 5' UTRs can selectively increase protein levels.
    Liang XH; Sun H; Shen W; Wang S; Yao J; Migawa MT; Bui HH; Damle SS; Riney S; Graham MJ; Crooke RM; Crooke ST
    Nucleic Acids Res; 2017 Sep; 45(16):9528-9546. PubMed ID: 28934489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2'-Modified oligonucleotides for antisense therapeutics.
    Prakash TP; Bhat B
    Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
    Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
    Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein kinase Cbeta1, a major regulator of TCR-CD28-activated signal transduction leading to IL-2 gene transcription and secretion.
    Dreikhausen UE; Gorf K; Resch K; Szamel M
    Int Immunol; 2003 Sep; 15(9):1089-98. PubMed ID: 12917261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide.
    Shen L; Dean NM; Glazer RI
    Mol Pharmacol; 1999 Feb; 55(2):396-402. PubMed ID: 9927633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides.
    Boiziau C; Thuong NT; Toulmé JJ
    Proc Natl Acad Sci U S A; 1992 Jan; 89(2):768-72. PubMed ID: 1370586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short-term and long-term modulation of gene expression by antisense therapeutics.
    Sazani P; Vacek MM; Kole R
    Curr Opin Biotechnol; 2002 Oct; 13(5):468-72. PubMed ID: 12459339
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antisense therapy in clinical oncology: preclinical and clinical experiences.
    Tamm I
    Methods Mol Med; 2005; 106():113-34. PubMed ID: 15375315
    [No Abstract]   [Full Text] [Related]  

  • 53. Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA.
    Frieden M; Christensen SM; Mikkelsen ND; Rosenbohm C; Thrue CA; Westergaard M; Hansen HF; Ørum H; Koch T
    Nucleic Acids Res; 2003 Nov; 31(21):6365-72. PubMed ID: 14576324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
    Soldatenkov VA; Dritschilo A; Wang FH; Olah Z; Anderson WB; Kasid U
    Cancer J Sci Am; 1997; 3(1):13-20. PubMed ID: 9072302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to antisense oligonucleotides by application of secondary structure predictions and RNase H in combination with MALDI-TOF mass spectrometry.
    Gabler A; Krebs S; Seichter D; Förster M
    Nucleic Acids Res; 2003 Aug; 31(15):e79. PubMed ID: 12888531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of RNA secondary structure on cellular antisense activity.
    Vickers TA; Wyatt JR; Freier SM
    Nucleic Acids Res; 2000 Mar; 28(6):1340-7. PubMed ID: 10684928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protein kinase C as a target for cancer therapy.
    Glazer RI
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):235-8. PubMed ID: 9212917
    [No Abstract]   [Full Text] [Related]  

  • 58. Antisense properties of 2'-O-dimethylaminooxyethyl (2'-O-DMAOE) oligonucleotides.
    Prakash TP; Kawasaki AM; Johnston JF; Graham MJ; Condon TP; Manoharan M
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):829-32. PubMed ID: 11563125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation.
    Manoharan M
    Biochim Biophys Acta; 1999 Dec; 1489(1):117-30. PubMed ID: 10807002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW 267.4 macrophage cells: a role of Raf-1 in lipopolysaccharide signaling.
    Chakravortty D; Kato Y; Sugiyama T; Koide N; Mu MM; Yoshida T; Yokochi T
    J Immunol; 2001 Feb; 166(3):2011-7. PubMed ID: 11160250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.